Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031271

Enrollment

Unknown

Registered

2020-03-26

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Control group:regular treatment

Experimental group:Compound amino acid combined with routine treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Novel coronavirus pneumonia diagnosis and treatment plan (trial version seventh) was revised to meet the diagnostic criteria of the 18-65 year old patients

Exclusion criteria

Exclusion criteria: (1) Basic diseases: Patients with severe diabetes, cardiopulmonary insufficiency, chronic kidney disease, chronic liver failure, cirrhosis, etc. before onset; tumor patients; patients with azotemia; (2) Not willing to participate in the experiment;

Design outcomes

Primary

Measure	Time frame
Hospital stay or death ratio of experimental group / death ratio of control group;	—

Secondary

Measure	Time frame
SOFA;Serum inflammatory factor concentration;ICU inpatient days;Quality of life assessment in 90 day follow-up;	—

Countries

China

Contacts

Public ContactZhuang-Gui Chen

Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-sen University

chenzhuanggui@126.com+86 13600009221

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026